Similarly, an effect was observed in response to modified citrus pectin (MCP) on cancer [67,95,194,195]; however, MCP can also be used for other Gal-related disease treatments, such as decreasing Gal-3 levels in type 2 diabetes [196], decreasing doxorubicin-induced cardiovascular diseases [197], ameliorating cardiac dysfunction [198], and improving ischemic heart failure [199]. Here, LGALS3 is linked to type 2 diabetes mellitus.